Literature DB >> 18585405

Sex and opioid maintenance dose influence response to naloxone in opioid-dependent humans: a retrospective analysis.

Mohit P Chopra1, Zachary Feldman, Michael J Mancino, Alison Oliveto.   

Abstract

Pooled self-report and physiological data from 32 male and 15 female methadone or levo-alpha-acetyl methadol (LAAM) maintained volunteers were retrospectively analyzed for individual differences in response to naloxone (0.15 mg/70 kg, IM) and placebo at 20 and 40 min post-injection. Males and females were each divided by the median splitmethadone maintenance dose (MMD, in mg/kg body weight) into high and low MMD groups and MMD was used as a factor in the analyses, along with sex, drug, and time post-drug. Females in the low but not high, MMD group showed naloxone-induced increases in ratings on the Antagonist and Mixed-Action sub-scales of the Adjective Rating Scale, and the Lysergic acid diethyl amine (LSD) sub-scale of the Addiction Research Center Inventory at 20 min post-injection. Males in the high MMD group showed significant naloxone-induced increases in scores of these measures at both post-injection time-points. In addition, low MMD subjects showed more short-lived naloxone-induced increases on Visual Analogue Scale (VAS) Bad and Any drug effects ratings than high MMD subjects. These results suggest that those on a lower MMD, especially women, experience a more intense, but short-lived, response to naloxone, whereas those on a higher MMD experience a more modest, but longer-lasting effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18585405      PMCID: PMC2577173          DOI: 10.1016/j.pbb.2008.05.023

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  45 in total

Review 1.  Sex and estrogen influence drug abuse.

Authors:  Marilyn E Carroll; Wendy J Lynch; Megan E Roth; Andrew D Morgan; Kelly P Cosgrove
Journal:  Trends Pharmacol Sci       Date:  2004-05       Impact factor: 14.819

Review 2.  Low efficacy opioids: implications for sex differences in opioid antinociception.

Authors:  Andrew C Barrett
Journal:  Exp Clin Psychopharmacol       Date:  2006-02       Impact factor: 3.157

3.  Butorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure.

Authors:  Alison Oliveto; Kevin Sevarino; Elinore McCance-Katz; Alan Feingold
Journal:  Pharmacol Biochem Behav       Date:  2002 Jan-Feb       Impact factor: 3.533

4.  High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.

Authors:  Eric C Donny; Sharon L Walsh; George E Bigelow; Thomas Eissenberg; Maxine L Stitzer
Journal:  Psychopharmacology (Berl)       Date:  2002-03-13       Impact factor: 4.530

5.  Triazolam discrimination by humans under a novel response procedure: effects of buspirone and lorazepam.

Authors:  J.B. Kamien; W.K. Bickel; A.H. Oliveto; B.J. Smith; S.T. Higgins; J.R. Hughes; G.J. Badger
Journal:  Behav Pharmacol       Date:  1994-06       Impact factor: 2.293

6.  A 33-year follow-up of narcotics addicts.

Authors:  Y I Hser; V Hoffman; C E Grella; M D Anglin
Journal:  Arch Gen Psychiatry       Date:  2001-05

7.  Morphine-induced conditioned place preference in preweanling and adult rats.

Authors:  C K Randall; P J Kraemer; M T Bardo
Journal:  Pharmacol Biochem Behav       Date:  1998-05       Impact factor: 3.533

8.  The effects of a cold-water stimulus on butorphanol effects in males and females.

Authors:  James P Zacny; Nancy J Beckman
Journal:  Pharmacol Biochem Behav       Date:  2004-08       Impact factor: 3.533

9.  Effects of diazepam and hydromorphone in triazolam-trained humans under a novel-response drug discrimination procedure.

Authors:  A H Oliveto; W K Bickel; J B Kamien; J R Hughes; S T Higgins
Journal:  Psychopharmacology (Berl)       Date:  1994-04       Impact factor: 4.530

10.  Clonidine and yohimbine in opioid-dependent humans responding under a naloxone novel-response discrimination procedure.

Authors:  A Oliveto; K Sevarino; E McCance-Katz; T Benios; J Poling; A Feingold
Journal:  Behav Pharmacol       Date:  2003-03       Impact factor: 2.293

View more
  5 in total

1.  Examining the factor structure of the Clinical Opiate Withdrawal Scale: A secondary data analysis from the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003.

Authors:  Celestina Barbosa-Leiker; Sterling McPherson; Mary Rose Mamey; G Leonard Burns; Matthew E Layton; John Roll; Walter Ling
Journal:  Drug Alcohol Depend       Date:  2015-04-11       Impact factor: 4.492

2.  Ondansetron Does Not Reduce Withdrawal in Patients With Physical Dependence on Chronic Opioid Therapy.

Authors:  Larry F Chu; John Sun; Anna Clemenson; Matthew J Erlendson; Tom Rico; Erika Cornell; Hannah Obasi; Zahra N Sayyid; Ellen M Encisco; Jeff Yu; Jamison G Gamble; Ian Carroll; J David Clark
Journal:  J Addict Med       Date:  2017 Sep/Oct       Impact factor: 3.702

3.  Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.

Authors:  Kelly E Dunn; Elise M Weerts; Andrew S Huhn; Jennifer R Schroeder; David Andrew Tompkins; George E Bigelow; Eric C Strain
Journal:  Addict Biol       Date:  2018-10-08       Impact factor: 4.280

Review 4.  Gender differences in pharmacokinetics and pharmacodynamics of methadone substitution therapy.

Authors:  Manuela Graziani; Robert Nisticò
Journal:  Front Pharmacol       Date:  2015-06-09       Impact factor: 5.810

5.  A buprenorphine-validated rat model of opioid use disorder optimized to study sex differences in vulnerability to relapse.

Authors:  Anousheh Bakhti-Suroosh; Eleanor Blair Towers; Wendy J Lynch
Journal:  Psychopharmacology (Berl)       Date:  2021-01-06       Impact factor: 4.415

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.